How Pluvicto and Lutetium-177 Work in Prostate Cancer
Pluvicto, a lutetium-177 radioligand therapy, targets PSMA-positive metastatic prostate cancer — here's how it works and who qualifies.
castration-resistant prostate cancer
Pluvicto, a lutetium-177 radioligand therapy, targets PSMA-positive metastatic prostate cancer — here's how it works and who qualifies.